These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16779730)

  • 21. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
    Snape MD; Kelly DF; Green B; Moxon ER; Borrow R; Pollard AJ
    Pediatr Infect Dis J; 2005 Feb; 24(2):128-31. PubMed ID: 15702040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
    Snape MD; Philip J; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Kittel C; Toneatto D; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2013 Oct; 32(10):1116-21. PubMed ID: 23958808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.
    de Voer RM; van der Klis FR; Engels CW; Schepp RM; van de Kassteele J; Sanders EA; Rijkers GT; Berbers GA
    Vaccine; 2009 Nov; 27(50):6974-82. PubMed ID: 19800445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
    Buttery JP; Riddell A; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Harnden A; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
    JAMA; 2005 Apr; 293(14):1751-8. PubMed ID: 15827314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.
    Ishola DA; Borrow R; Findlow H; Findlow J; Trotter C; Ramsay ME
    Clin Vaccine Immunol; 2012 Aug; 19(8):1126-30. PubMed ID: 22647271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
    Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?
    Tsai TF; Borrow R; Gnehm HE; Vaudaux B; Heininger U; Desgrandchamps D; Aebi C; Balmer P; Pedersen RD; Fritzell B; Siegrist CA
    Clin Vaccine Immunol; 2006 Aug; 13(8):854-61. PubMed ID: 16893984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan.
    Flitter BA; Ismail A; Vu D; Granoff DM
    Hum Vaccin; 2007; 3(4):135-8. PubMed ID: 17581284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on immunogenicity of group A and group C meningococcal conjugate vaccine with coupling group B meningococcal outer membrane protein].
    Ma FB; Tao H; Wang HJ
    Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):451-5. PubMed ID: 20084975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children.
    Granoff DM; Morgan A; Welsch JA
    Vaccine; 2005 Jul; 23(34):4307-14. PubMed ID: 15921829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
    Blanchard-Rohner G; Watt H; Kelly DF; Yu LM; Snape MD; Pollard AJ
    Vaccine; 2012 Jun; 30(28):4153-9. PubMed ID: 22554466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
    Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization strategies for the control of serogroup C meningococcal disease in developed countries.
    De Wals P
    Expert Rev Vaccines; 2006 Apr; 5(2):269-75. PubMed ID: 16608426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.